⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AMGN
PFE
LLY
AZN
BMY
NVS
SNY
GSK
UCB
ARQT
REGN
INCY
ABBV
BIIB
MRK
JNJ
VNDA
RAPT
CHAI
ONON
ION
ASMB
CRVS
APG
KSCP
KYMR
XBI
IBB
ADSK
CDNS
SNPS
Neuroblastoma Market - A Global and Regional Analysis: Focus on Treatment and Regional Analysis - Analysis and Forecast, 2025-2035
globenewswire.com
NVS
LLY
Global Demand Spurs Competition in CAR T-Cell Therapy for Multiple Myeloma
globenewswire.com
BMY
JNJ
NVS
GILD
John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), to Deliver Keynote Address on the Future of Biotech and Rare Disease Innovation at the 2026 MDA Clinical & Scientific Conference
globenewswire.com
AMGN
REGN
GILD
BMY
AZN
NVS
ARGX
BIIB
BBIO
SRRK
CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035 by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players
globenewswire.com
BMY
GILD
NVS
Basal Cell Carcinoma Market Poised for Steady Growth Throughout Forecast Period (2025-2034) Driven by Novel Drug Approvals and Expanding Patient Pool | DelveInsight
prnewswire.com
VRCA
REGN
NVS
GENK
INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
prnewswire.com
NVS
Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer
globenewswire.com
AZN
NVS
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
prnewswire.com
CRNX
NVS
Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight
globenewswire.com
LUN
LLY
AMGN
NVS
TEVA
ALLER
BHVN
DRREDDY
ABBV
IMPL
ZSAN
AXSM
AEON
IONS
CHRC
AZN
GSK
WSTN